Pitolisant治疗拒绝CPAP的阻塞性睡眠呼吸暂停患者日间嗜睡:一项随机试验
这项国际多中心双盲随机安慰剂对照试验纳入268例拒绝或不依从CPAP的中重度OSA患者,按3:1随机接受pitolisant(滴定至20 mg/d)或安慰剂治疗12周。主要终点ESS评分在pitolisant组较安慰剂组多降低2.8分(95%CI -4.0至-1.5,P<0.001),疲劳及患者/医生报告结局改善,觉醒维持测试未改善,不良事件发生率两组相似。
要点
- Pitolisant可显著降低拒绝CPAP的OSA患者ESS嗜睡评分,较安慰剂多降2.8分。
- 疲劳评分及患者、医生报告结局改善,但觉醒维持测试未改善。
- 不良事件以头痛、失眠、恶心、眩晕为主,两组发生率相似,无心血管安全信号。
核心结论
- Pitolisant显著降低拒绝或不依从CPAP的嗜睡OSA患者自报日间嗜睡和疲劳,并改善患者报告结局及医生疾病严重度评估。
研究设计与样本
- 国际多中心、双盲、随机(3:1)、安慰剂对照、平行设计试验,pitolisant在12周内个体化滴定至最高20 mg/d。
- 共268例中重度OSA患者随机(pitolisant 200例,安慰剂68例),按意向治疗分析;75%男性,平均年龄52岁,AHI 49/h,基线嗜睡评分15.7。
主要发现
- ESS评分在pitolisant组较安慰剂组多降低2.8分(95%CI -4.0至-1.5,P<0.001)。
- 基于Oxford睡眠抵抗测试的觉醒维持未改善。
- Pichot疲劳评分在pitolisant组降低。
- 医生和患者问卷均证实pitolisant的总体效果。
- 不良事件发生率pitolisant组29.5%、安慰剂组25.4%,主要为头痛、失眠、恶心和眩晕,无心血管或其他显著安全性问题。
临床怎么用
- 对于拒绝或不依从CPAP的中重度OSA伴日间嗜睡患者,pitolisant可作为改善自报嗜睡和疲劳的药物治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome.Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the treatment of daytime sleepiness in patients with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure treatment.Methods: In an international, multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was individually titrated at up to 20 mg/d over 12 weeks. The primary endpoint was the change in the Epworth Sleepiness Scale score. Key secondary endpoints were maintenance of wakefulness assessed on the basis of the Oxford Sleep Resistance test, safety, Clinical Global Impression of severity, patient's global opinion, EuroQol quality-of-life questionnaire, and Pichot fatigue questionnaire.Measurements and Main Results: A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea-hypopnea index, 49/h; baseline sleepiness score, 15.7) were randomized (200 to pitolisant and 68 to placebo) and analyzed on an intention-to-treat basis. The Epworth Sleepiness Scale score was reduced more with pitolisant than with placebo (-2.8; 95% confidence interval, -4.0 to -1.5; P < 0.001). Wake maintenance tests were not improved. The Pichot fatigue score was reduced with pitolisant. The overall impact of pitolisant was confirmed by both physicians' and patients' questionnaires. Adverse event incidence, mainly headache, insomnia, nausea, and vertigo, was similar in the pitolisant and placebo groups (29.5% and 25.4%, respectively), with no cardiovascular or other significant safety concerns.Conclusions: Pitolisant significantly reduced self-reported daytime sleepiness and fatigue and improved patient-reported outcomes and physician disease severity assessment in sleepy patients with obstructive sleep apnea refusing or nonadherent to continuous positive airway pressure.Clinical trial registered with www.clinicaltrials.gov (NCT01072968) and EU Clinical Trials Register (EudraCT 2009-017251-94).
引用
- Dauvilliers Y, Verbraecken J, Partinen M, et al. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial. Am J Respir Crit Care Med. 2020. PMID: 31917607. doi:10.1164/rccm.201907-1284OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。